BioPharma

Allergan Chairman and Chief Executive Officer Brent Saunders talks about how he built up the pharmaceutical giant, the pending sale of Allergan to Abbvie, why he took a huge pay cut to come to Allergan, and the controversial subject of drug pricing.

There is no best-case drug pricing scenario for the drug industry in 2020.

Beijing’s health-care reforms are giving global pharmaceutical companies better access to the world’s second-largest drug market.

Drug store chain Walgreens will go on trial next year for its role in the US opioid crisis while its co-defendants have settled out of court.

BioCorRx implanted an anti-opioid treatment in an incarcerated person earlier this year. But the procedure hadn’t been approved by the FDA.

Today, three companies control virtually the entire global market for insulin.

Pharmaceutical and health insurance industry representatives on Wednesday sparred over the potential impacts of legislation to lower drug prices, underscoring an emerging flashpoint.

Financial conflict of interest in cancer medicine matters. The pharmaceutical industry is run by intelligent people who choose to pay physicians millions of dollars. It is hard to believe they have not calculated that this aids their bottom lines.

How psychiatric patients became victims.

America's secret drug pricing system.

Amgen Inc. will pull its higher-priced version of its cholesterol drug Repatha from the market, an effort to boost sales of the drug by offering only a lower-priced version of the product.

Starting next year, Repatha will list for $5,850 a year for all insurers.

Repatha’s initial price of more than $14,000 a year has been a deterrent to sales.

Average value of Gilead drug increased from US$ 16 to US$ 240.

The world’s most expensive drug - a record price tag of $2.1 million, or an annualized cost of $425,000 per year for five years - has been used to treat 100 patients since its launch and brought in $160 million for its maker.